- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05375058
Complicated Appendicitis During the COVID-19 Pandemic in Jordan
May 13, 2022 updated by: Abdallah Raed Al-Qawasmeh, Jordan University Hospital
Impact of the COVID-19 Pandemic on the Incidence of Complicated Appendicitis in a Tertiary Medical Center, Amman, Jordan: A Retrospective Cohort
Comparing the incidence of complicated appendicitis between two groups, the pandemic and pre-pandemic groups.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The investigators have retrospectively investigated data on acute appendicitis cases.
Two groups were established, the first group was the pandemic group, which included patients who presented to the hospital during the period of acute restrictions and shutdowns extending from the 17th of March to the 6th of June 2020, and the pre-pandemic group which represents the same period in the previous year, the aim was to assess the incidence of complicated appendicitis during the COVID-19 pandemic in Jordan University Hospital
Study Type
Observational
Enrollment (Actual)
257
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Amman, Jordan, 11942
- Jordan University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Any patient that has a medical record for appendicitis and underwent appendectomy at University of Jordan hospital
Description
Inclusion Criteria:
- Any patient that presented with appendicitis and underwent an appendectomy at the university of Jordan hospital during the specified time periods (March 2019-December 2020)
Exclusion Criteria:
- Incomplete data record.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
pandemic group (2020)
includes patients who presented to the hospital during the period of acute restrictions and shutdowns extending from the 17th of March to the 6th of June 2020
|
Observational Study; the study did not involve any interventions
|
|
pre-pandemic group (2019)
which represents the same period in the previous year
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Occurrence of postoperative complications
Time Frame: Up to 2 years
|
To determine if there were any complications, this was detected by reviewing the histopathology report
|
Up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Length of in-hospital stay
Time Frame: Up to 2 years
|
How many days did the patient spend in the hospital until discharged.
|
Up to 2 years
|
|
Imaging method used for diagnosis (CT or US)
Time Frame: Up to 2 years
|
How was appendicitis diagnosed, either by using Computed Tomography (CT) Scan or Ultrasound.
|
Up to 2 years
|
|
Type of operation (open or laparoscopic)
Time Frame: Up to 2 years
|
We reported what type of operation the patient underwent to treat appendicitis.
|
Up to 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Marzouq Amarin, MD, MSc, Department of General Surgery, the University of Jordan, Amman, 11942, Jordan
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 2, 2019
Primary Completion (Actual)
December 28, 2020
Study Completion (Actual)
December 28, 2020
Study Registration Dates
First Submitted
May 11, 2022
First Submitted That Met QC Criteria
May 13, 2022
First Posted (Actual)
May 16, 2022
Study Record Updates
Last Update Posted (Actual)
May 16, 2022
Last Update Submitted That Met QC Criteria
May 13, 2022
Last Verified
May 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Gastrointestinal Diseases
- Gastroenteritis
- Intestinal Diseases
- Cecal Diseases
- Intraabdominal Infections
- COVID-19
- Appendicitis
Other Study ID Numbers
- 28/2021
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.